RxDoctor Payments Data

Sergey Zhitar, MD

Addiction Medicine · Virginia Beach, VANPI 1881639375

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Orexo US, Inc. at 28.3% of the total. Reporting peaked in 2019 at $444 and has fallen 96.6% since, to $15 in 2022.

$518in general payments, 2019–2025

Across 18 payments — averaging $28.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Orexo US, Inc.$147
  • Kaleo, Inc.$107
  • AbbVie$97
  • Alkermes, Inc.$70
  • MDD US Operations, LLC$27
  • Indivior Inc.$23
  • plus $46 from 3 others

What the payments were for

  • Food & beverage$518100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Orexo US, Inc.7$147
Kaleo, Inc.1$107
AbbVie1$97
Alkermes, Inc.4$70
MDD US Operations, LLC1$27
Indivior Inc.1$23
Titan Pharmaceuticals, Inc.1$16
Gilead1$15
Almatica Pharma LLC1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$518 in reported general payments places this provider in the 70th percentile of 44 addiction medicine providers in Virginia.

See all addiction medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$68,859
Medicare patients
57
Services billed
1,003

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl19$15,681
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl124$8,817
Oxycodone Hcl158$4,519
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen136$3,101
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen110$2,548
Celecoxib63$2,281
Pregabalin86$2,068
Naloxone Hcl38$1,494
Gabapentin99$717
Ondansetron OdtOndansetron19$691
Duloxetine Hcl30$522
Morphine Sulfate ErMorphine Sulfate21$421
Tramadol Hcl23$316
Cyclobenzaprine Hcl37$279
Methadone Hcl20$266

Paid to pharmacies, not to this prescriber.

Other addiction medicine in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →